A detailed history of Steph & CO transactions in Argenx Se stock. As of the latest transaction made, Steph & CO holds 401 shares of ARGX stock, worth $252,625. This represents 0.08% of its overall portfolio holdings.

Number of Shares
401
Previous 415 3.37%
Holding current value
$252,625
Previous $178,000 21.91%
% of portfolio
0.08%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$434.22 - $551.9 $6,079 - $7,726
-14 Reduced 3.37%
401 $217,000
Q2 2024

Jul 30, 2024

BUY
$356.01 - $451.55 $712 - $903
2 Added 0.48%
415 $178,000
Q1 2024

Apr 12, 2024

BUY
$356.95 - $413.29 $31,411 - $36,369
88 Added 27.08%
413 $162,000
Q4 2023

Jan 31, 2024

BUY
$338.91 - $506.01 $7,794 - $11,638
23 Added 7.62%
325 $123,000
Q3 2023

Oct 26, 2023

BUY
$369.35 - $548.43 $111,543 - $165,625
302 New
302 $148,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Steph & CO Portfolio

Follow Steph & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steph & CO, based on Form 13F filings with the SEC.

News

Stay updated on Steph & CO with notifications on news.